Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/1078-0432.CCR-14-0932 http://scihub22266oqcxt.onion/10.1158/1078-0432.CCR-14-0932 C4155019!4155019 !25059519     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25059519 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Clin+Cancer+Res 2014 ; 20 (17 ): 4422-4 Nephropedia Template TP {{tp|p=25059519 |t=2014. "Companion diagnostics": has their time come and gone? |pdf=|usr=}}{{25059519 }} gab.com Text "Companion diagnostics": has their time come and gone JO: Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=25059519 #FOAvip Rapid development of molecularly targeted drugs requires a "companion diagnostic" that could delay drug development and limit availability of active drugs for relevant patients. Were the negative results from MetMab studies in patients with advanced non-small cell lung cancer due to drug failure or failure of the right companion diagnostic? Twit Text FOAVip "Companion diagnostics": has their time come and gone ????Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=25059519 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25059519 #FOAvip English Wikipedia <ref>{{Cite pmid|25059519 }}</ref> "Companion diagnostics": has their time come and gone? #MMPMID25059519 Hirsch FR ; Bunn PA Jr ; Herbst RS Clin Cancer Res 2014[Sep]; 20 (17 ): 4422-4 PMID25059519 show ga Rapid development of molecularly targeted drugs requires a "companion diagnostic" that could delay drug development and limit availability of active drugs for relevant patients. Were the negative results from MetMab studies in patients with advanced non-small cell lung cancer due to drug failure or failure of the right companion diagnostic? |Antibodies, Monoclonal/*administration & dosage [MESH] |Antineoplastic Combined Chemotherapy Protocols/*administration & dosage [MESH] |Carcinoma, Non-Small-Cell Lung/*drug therapy [MESH] |Erlotinib Hydrochloride [MESH] |Female [MESH] |Humans [MESH] |Male [MESH] |Proto-Oncogene Proteins c-met/*biosynthesis [MESH]"Companion diagnostics": has their time come and gone? (epmc).pdf DeepDyve Pubget Overpricing